|
Most surgical procedures do not require prophylactic or postoperative antibiotics. However, certain patient-related and procedure-related factors alter the risk-benefit ratio in favor of prophylactic use.
Patient-related factors include certain valvular heart disorders and immunosuppression. Procedures with higher risk involve areas where bacterial seeding is likely:
In so-called clean (likely to be sterile) procedures, prophylaxis generally is beneficial only when prosthetic material or devices are being inserted or when the consequence of infection is known to be serious (eg, mediastinitis after coronary artery bypass grafting).
Drug choice is based on the bacteria most likely to contaminate the wound during a specific procedure. For commonly recommended regimens by procedure, see Table 2: Care of the Surgical Patient: Antimicrobial Preoperative Prophylaxis Guidelines . Prophylaxis requires that the appropriate antibiotic is given within 1 h before the procedure. Antibiotics may be given orally or IV, depending on the procedure. The need for additional doses after the procedure is controversial, but for clean operations, no additional doses are needed. Postoperative antibiotics are continued > 24 h only when an active infection is detected during surgery; antibiotics are then considered treatment, not prophylaxis.
|
Table 2
|
PrintOpen table in new window  |
 |  |  |
| Antimicrobial Preoperative Prophylaxis Guidelines |
|
Category
|
Procedure
|
Adult Dosage*
|
|
Abdominal
|
Gastroduodenal surgery in patients with hemorrhage, cancer, obstruction, or other high-risk features
|
Cefazolin 1–2 g IV preoperatively
or
Clindamycin 600 mg plus gentamicin 120 mg IV preoperatively
|
|
Gastric bypass
|
Cefazolin 1–2 g IV preoperatively
|
|
Percutaneous gastrostomy
|
Cefazolin 1–2 g IV preoperatively
|
|
Biliary tract (including ERCP) in patients who have acute symptoms, jaundice, or other high-risk features or who have had previous surgery
|
Cefazolin 1–2 g IV preoperatively
or
Gentamicin 80 mg IV preoperatively and q 8 h for 3 doses
|
|
Appendectomy (without perforation)
|
Cefoxitin, cefotetan, or cefmetazole 1–2 g IV preoperatively and q 6 h for 3 doses
or
Metronidazole 500 IV mg plus gentamicin 1.5 mg/kg IV preoperatively
|
|
Colorectal surgery, elective
|
Neomycin 1 g plus erythromycin base 1 g po at 1, 2, and 11 pm on the day before surgery ± parenteral drugs listed below for colorectal surgery
|
|
Colorectal surgery, emergency
|
Cefoxitin, cefotetan, or cefmetazole 2 g IV preoperatively and q 4 h for 3 doses
or
Metronidazole 500 mg IV plus gentamicin 1.7 mg/kg IV preoperatively and q 8 h for 3 doses
|
|
Cardiac
|
Median sternotomy, coronary artery bypass graft surgery, valve surgery, or pacemaker insertion
|
Cefazolin 2 g IV preoperatively and q 4–6 h intraoperatively
or
Cefuroxime 1.5 g IV preoperatively and q 4–6 h intraoperatively
or
Vancomycin 1 g IV preoperatively
|
|
Neurosurgical
|
Craniotomy, high-risk only (eg, reexplorations, microsurgery, entry into sinuses or nasopharynx)
|
Vancomycin 1g IV plus gentamicin 1.5 mg/kg IV preoperatively
or
Cefazolin 1 g IV preoperatively
|
|
CSF shunt placement—only in hospitals with high infection rates (15–20%)
|
Trimethoprim 160 mg IV plus sulfamethoxazole 800 mg IV preoperatively and q 12 h for 3 doses
or
Vancomycin 10 mg plus gentamicin 3 mg injected into a cerebral ventricle
|
|
Noncardiac thoracic
|
Pneumonectomy, lobectomy, other resections, or esophageal surgery
|
Cefazolin 1–2 g IV preoperatively and q 6 h for 24 h
or
Vancomycin 1 g IV preoperatively
|
|
Obstetric-gynecologic
|
Cesarean delivery, high-risk only (eg, premature rupture of membranes)
|
Cefazolin 1 g IV after clamping cord and q 6 h for 2 doses
|
|
Abortion, 2nd-trimester instillation
|
Cefazolin 1 g IV preoperatively and q 6 h for 2 doses
|
|
Abortion, 1st trimester in patients with a history of pelvic inflammatory disease, gonorrhea, or multiple partners
|
Penicillin G 1–2 million units IV preoperatively and 3 h later
or
Doxycycline 100 mg po before the procedure and 200 mg ½ h afterward
|
|
Hysterectomy, vaginal or abdominal
|
Cefazolin 1 g IV preoperatively and q 6 h for 2 doses
or
Doxycycline 200 mg IV preoperatively
|
|
Ophthalmic
|
Extraction of lens, with or without insertion of prosthesis
|
Gentamicin, tobramycin, or neomycin-gramicidin-polymyxin B drops over 2–24 h plus cefazolin 100 mg subconjunctivally at the end of the procedure
|
|
Orthopedic
|
Arthroplasty, including replacements
|
Cefazolin 1–2 g IV preoperatively and q 6 h for 3 doses
or
Vancomycin 1 g IV preoperatively
|
|
Open reduction of fractures
|
Cefazolin 1 g IV preoperatively and as a single dose postoperatively
|
|
Lower-extremity amputation (nonischemic)
|
Cefoxitin 2 g IV preoperatively and q 6 h for 4 doses
|
|
Otolaryngologic
|
Major head and neck surgery involving mucosa of the oral cavity or pharynx
|
Cefazolin 1–2 g IV preoperatively and q 8 h for 2 doses
or
Clindamycin 600–900 mg IV ± gentamicin 1.5 mg/kg IV preoperatively and q 8 h for 2 doses
|
|
Urologic
|
Prostatectomy if bacteriuria is present
|
Cefazolin 1 g IV preoperatively or another drug selected based on susceptibility tests
|
|
Penile prosthesis insertion
|
Cefazolin 1 g IV preoperatively
|
|
Vascular
|
Lower-extremity or abdominal arterial surgery or lower- extremity amputation for ischemia
|
Cefazolin 1–2 g IV preoperatively and q 6 h for 24 h
or
Vancomycin 1 g IV preoperatively and 12 h after the procedure
|
|
*Drugs, dosages, routes, and frequencies given represent recent expert recommendations. Cefazolin remains highly favored because of its spectrum of bactericidal activity, long half-life, low cost, and low toxicity. Alternatives are primarily for patients with β-lactam allergies.
|
|
± = with or without.
|
|
Adapted from Kernodle DS, Kaiser AB: Postoperative infections and antimicrobial prophylaxis. In Principles and Practice of Infectious Diseases, ed 5, edited by GL Mandell, JE Bennett, and R Dolin. New York, Churchill Livingstone, 2000, pp. 3186–3187 and from Antimicrobial prophylaxis in surgery. The Medical Letter 37:79–82, 1995.
|
|
Last full review/revision May 2009 by Robert G. Johnson, MD
|